LRP1 and cancer: Importantly, IGFBP-3R (TMEM219) agonists, in particular TMEM219 agonistic mAbs, are very attractive cancer therapeutics since these agonists would exhibit no other biological activities of IGFBP-3 induced by the interaction with other binding partners.